VRDN
Viridian Therapeutics, Inc.
$16.61
-2.29%
2026-05-08
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
-6.89
EPS (TTM)
$-3.35
ROE
-58.1%
Revenue Growth (YoY)
95.8%
Profit Margin
0.0%
Debt/Equity
8.39
Price/Book
2.91
Beta
0.82
Market Cap
$1.74B
Avg Volume (10D)
4.6M
Recent Breakout Signals
No recent breakout signals detected for VRDN.
Recent Price Range (60 Days)
60D High
$30.79
60D Low
$13.19
Avg Volume
2.7M
Latest Close
$16.61
Get breakout alerts for VRDN
Sign up for Breakout Scanner to receive daily notifications when VRDN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Viridian Therapeutics, Inc. (VRDN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VRDN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VRDN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.